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in South Africa where dideoxynucleosides are used as nucle-
oside backbones for HAART in the public sector. This study
reviews the incidence, characteristics, analysis frequently
reported symptoms and documents outcomes of SHL and LA.
Method: Retrospective cohort analysis was performed
of 1175 adults (66.5% female) who started on ART from
January 2004 to January 2007 at the Tygerberg Hospital
Infectious Diseases Clinic. All patients with two lactate lev-
els of >2,5mmol/l and symptoms compatible with SHL during
the study period were included in the analysis.
Results: A total of 79 patients presented with SHL (65
female). The overall incidence was 42 cases per 1000
patient- years. The incidence among female patients was
36.1 cases per 1000 p-y compared to 6.1 cases per 1000 p-y
on treatment among male patients. 46 patients (58%) had
lactate measurements of >5mmol/l giving it and incidence
of 22 cases per 1000 p-y. Two patients (2, 5%) died. Median
age was 37 years, median baseline CD4 102 and median dura-
tion of ART was 11 months. The baseline median BMI was 24,
1. Seventeen (23, 6%) of 72 patients with SHL were obese
(BMI > 30). All 79 patients were on d4T prior to develop-
ing SHL. Most frequently reported symptoms were weight
loss (61%), nausea and vomiting 58%, abdominal pain or ten-
derness 55% and peripheral neuropathy occurred in 51% of
patients. Of the 70 patients restarted or continued with AZT
only 1 patient developed a recurrence.
Conclusion: A higher incidence was found as the cohort
included the entire spectrum of SHL. The frequency of SHL
was higher among women. The low mortality in this cohort
is likely due to increased awareness of clinicians and due
to inclusion of mild to moderate forms of SHL. AZT seems
a safe alternative where NRTI options are limited. These
ﬁndings mirror results found in other South African cohort
in the public sector ARV roll-out program.
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The Government of Tanzania launched ARV programme
for PLHA since 2003, with the aim of decrease suppression
of HIV replication, improve patient’s survival and to reduce
morbidity. At Ligula hospital in Mtwara Municipal where this
study was conducted, the programme was introduced in
June 2005. This dissertation attempts to describe a study
conducted to identify the factors contributing to ARV non-
adherence among PLHA attending CTC at Ligula hospital.
This study was under taken during October 2006 with 50
respondents who included 45 ARV users and ﬁve (5) service
providers. The respondents were selected by using simple
random sampling method. Data was collected by using a
semi-structured questionnaire, and then data analysis was
done manually.
Majority (60%) of respondents reported to have had failed
to adhere to prescribed regimen. The reasons for non-
adherence included; 55% lack of privacy, 44.4% long distance
to hospital, 44.4% out of their home and 41% simply forgot
33.3% don’t want to be notice, 25% alternative therapy, 15%
side effect of drug. When reporting about non-adherence,
the interviewed service providers mentioned the use of tra-
ditional medicine 80%, low capacity of client to understand
80% economic constraints 60%, lack of support 40%, long
distance to clinic 20%, side effect 20%, and feels recovery
20%.
This study concludes that, factors for ARV’s non-
adherence are multi-factorial. These results are useful in
planning interventions to promote medication adherence
among clients receiving ARV at Ligula hospital and similar
settings. Both clients and providers should be targeted by
interventions aimed at improving adherence to ARVs.
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Background: Due to limited regimen options in resource-
limited settings, it is important to maximize the durability of
response to ﬁrst-line antiretroviral therapy in order to opti-
mize patient outcomes and maintain lower program costs.
Objectives: To conduct a pilot study of initiation of a one-
month period of directly administered antiretroviral therapy
(DAART) for participants with suspected ﬁrst-line treatment
failure. The primary outcome was the change in CD4 lym-
phocyte count following DAART.
Methods: We conducted a prospective cohort study in
Mombasa, Kenya between 2004 and 2007. We identiﬁed all
women on ART who met WHO criteria for immunological
treatment failure but were clinically stable. These women
received four weeks of DAART, during which we directly
administered the morning dose at the clinic for ﬁve days
each week.
Results: Fourteen women resumed DAART. The median
time to suspected treatment failure was 428 days (interquar-
tile range [IQR], 333—819 days), and the median CD4 cell
count at treatment failure was 152 cells/microliter (IQR,
112—232). Following one month of DAART, 5 women were
diagnosed with treatment failure, while 9 women were
no longer classiﬁed as failing. Among those who failed,
the median CD4 counts were 153 cells/microliter (IQR, 63-
